A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study
| Autor: | Shigenori Ando, Hiroyuki Ito, Suzuko Matsumoto, Toshiko Mori, Tomoko Yamasaki, Shinya Nishio, Emiko Tsugami, Kosuke Uemura, Michiko Togane, Shinichi Antoku, Rie Araki |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Insulin glargine business.industry type 2 diabetes mellitus Basal insulin Diabetes Clinical course Type 2 Diabetes Mellitus 030209 endocrinology & metabolism Biosimilar General Medicine Hypoglycemia medicine.disease 03 medical and health sciences 0302 clinical medicine hypoglycemia Internal medicine Propensity score matching medicine 030212 general & internal medicine biosimilar business medicine.drug |
| Zdroj: | Journal of Drug Assessment |
| ISSN: | 2155-6660 |
| Popis: | Objective: We compared the clinical course of type 2 diabetic patients whose basal insulin preparations were replaced from insulin glargine (IGlar) 100 units/mL (U100) to IGlar biosimilar or IGlar 300 units/mL (U300). Methods: After propensity score matching, 34 patients whose basal insulin preparation was switched from IGlar U100 to IGlar biosimilar and 102 switched to IGlar U300 were observed for 6 months. Results: The HbA1c level and body weight did not change significantly after the replacement in the IGlar biosimilar or IGlar U300 groups. In the IGlar biosimilar group, the frequency of subjects who experienced hypoglycemia after the replacement (12%) was not different from before (12%). However, the frequency was significantly lower after the replacement (2%) than before (13%) in the IGlar U300 group. The change in the HbA1c level after the replacement showed a significant association with the HbA1c level at the baseline but not with the kind of IGlar. Hypoglycemia was frequently observed in subjects who had experienced hypoglycemia before the replacement. Conclusions: IGlar biosimilar and IGlar U300 induced similar HbA1c and body weight changes among type 2 diabetic patients. IGlar biosimilar is a suitable option for patients with a low risk for hypoglycemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|